text:
Home/Attorneys/James Scott Farrin Bolsters Formidable Roster of Attorneys
James Scott Farrin Bolsters Formidable Roster of Attorneys
Ye Wang March 25, 2021
0 1,636 1 minute read
DURHAM, N.C., March 25, 2021 /PRNewswire/ — The Law Offices of James Scott Farrin, one of the largest plaintiffs' firms in North Carolina, continues to grow. The firm recently added two new attorneys to its lineup of over 50 recognized professionals: Molly Brewer and Michael B. Eller. Brewer and Eller join a firm that recovered over $125 million in gross for over 4,500 clients in 2020.1
Brewer, a member of the North Carolina Advocates for Justice, believes that "victims deserve quality representation, an ally against the insurance companies, and the chance to turn things around after an injury." An active law professor, Brewer worked as a litigation paralegal before becoming a personal injury attorney.
Eller, a personal injury and workers' compensation attorney for over 16 years, has experience as both a solo practitioner and a large firm lawyer. An active volunteer in his community, Eller is licensed in multiple states and is a member of the American Association for Justice.
Brewer and Eller join a firm recently honored on the 2020 'Best Places to Work' list from the "Triangle Business Journal." The Law Offices of James Scott Farrin was also named on the 2021 'Best Law Firms' list by "U.S. News – Best Lawyers" for persistently impressive ratings from clients and peers.2
About The Law Offices of James Scott Farrin
The Law Offices of James Scott Farrin is one of the largest personal injury firms in North Carolina and has helped over 50,000 injured people since 1997. Operating from 16 offices in NC and one in SC, many of the firm's 50+ accomplished attorneys are recognized professionals in their fields. The firm focuses on providing quality legal services to as many people as possible in the following practice areas: personal injury, car accidents, workers' compensation, nursing home abuse, whistleblowing, defective products, eminent domain, mass torts, class actions, and Social Security Disability.
Offices in Durham (main), Raleigh, Charlotte, Greensboro, NC and Greenville, SC. Attorney J. Gabe Talton: 280 South Mangum St., Suite 400, Durham, NC.
David Chamberlin
280 S. Mangum Street
https://www.farrin.com/
1Prior results do not guarantee similar outcomes because each case is unique and must be evaluated separately.
2For information regarding the standards for inclusion for awards listed, visit www.bestlawyers.com and www.usnews.com.
SOURCE Law Offices of James Scott Farrin
http://www.farrin.com
LMPD interim chief intends to fireside 2 officers in Breonna Taylor case; right here's what occurs subsequent
Stormy Daniels and Michael Cohen, as soon as foes, speak Trump
County Approves Juvenile Courtroom Lawyer Listing
Pensacola attorneys maintain city corridor to debate lawsuit over bridge closure
St. Louis attorney's assertion on shopper not being pardoned in Capitol riot


text:
Flagship Journal
Microbiology & Infectious Diseases
Partners & Directory
You must accept all conditions before being able to view the post
Home Cardiology Interview: Dr Rasha Al-Lamee
Interview: Dr Rasha Al-Lamee
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
Dr Rasha Al-Lamee | Faculty of Medicine, National Heart & Lung Institute, London, UK
What do you find most interesting about complex coronary intervention and coronary physiology?
I went into cardiology to combine the science of medicine and the practical skills of surgery. I enjoy finding a problem and doing my best to fix it. Complex intervention presents continual challenges and stepwise, logical problem solving that keeps my job interesting. No two cases or 2 days in the catheterisation laboratory (cath lab) are the same. You never know what you will get and that keeps you on your toes! Coronary physiology adds more accuracy to what we do. It helps me to plan my procedures and make me feel surer of the result. I use physiology and intravascular imaging in the vast majority of my cases because I hate guesswork; I like to feel as certain as can be as I perform intervention.
In light of the global COVID-19 pandemic, what do you believe are the biggest challenges currently facing the clinical interventional cardiology community?
I think the greatest challenge we will have ahead of us is dealing with the collateral damage from COVID-19. The pandemic and lockdown have really had an impact on patient care. Many patients were dissuaded from seeking medical attention when they needed it. We are now seeing the knock-on effects from that as we recover and pick up the pieces. I also worry about the effect on cardiovascular morbidity and mortality because access to primary and secondary prevention was limited for some. I am concerned for the impact it has had on clinical research and clinical training. These are unprecedented times. I hope that we can get back on track as soon as we possibly can.
What motivated you to become a clinical triallist and what was the goal you set out to achieve when you embarked on this path?
In my mind one of the best aspects of cardiology is its strong evidence base. I love that from the beginning of our training we are taught to think about the science behind what we do. For me the most natural way to combine cardiology and academia was to design and conduct clinical trials. At an early stage in my training I was involved in recruitment and collecting data for studies in the UK. My interventional fellowship in Milan, Italy, taught me the importance of international collaboration and how clinical trials have shaped all the major developments in cardiology. I knew then that I wanted to start designing trials to answer my own clinical questions and it was the next natural step to embark upon a clinical trial for my PhD.
You conducted and led the Objective Randomised Blinded Investigation with Optimal Medical Therapy of Angioplasty in Stable Angina (ORBITA) trial. Could you elucidate the key findings?
The results of ORBITA were as surprising to me as they were to the many interventional cardiologists worldwide! This was the first placebo-controlled trial of angioplasty. The primary analysis showed a smaller than expected effect of angioplasty on treadmill exercise time and symptoms compared to placebo. The subsequent analyses showed even more interesting data: we found that one in five more patients reported being free from angina in the percutaneous coronary intervention (PCI) arm in a non-prespecified analysis. We also found that, when we stratified patients based on their pre-randomisation invasive physiology, the lower the fractional flow reserve (FFR) and the instantaneous wave-free ratio (iFR) index, the greater the placebo-controlled efficacy of PCI on improving stress echocardiography ischaemia. Also, the higher the pre-randomisation stress echocardiography score, the greater the improvement of frequency of angina with placebo-controlled PCI.
In your expert opinion, what key attributes are required for a successful clinical triallist, and what would be your advice to young scientists considering this career?
You need to find questions that truly need answering and design trials that will be clinically relevant and interesting. Completing any study is hard work and extremely challenging so, at the end of it, you should know it's something people will want to read about. Ideally the results of your trial will change practice but often that's very difficult, so you need to feel that your work will, at the very least, provide new data that add to the totality of our knowledge and will help us to make incremental steps towards the final answer.
As an advocate for rigorous testing of clinical practice and the use of evidence-based medicine in all phases of medical care, do you believe these standards are currently being upheld?
Yes, I do! I think we try very hard to uphold standards in medical care and use the evidence-base to inform what we do. Some teams are better than others at doing this, but in general I think cardiologists do a pretty good job at keeping up to date.
Overall, you have more than 70 publications and are actively involved in the development and recruitment for various multicentre clinical trials. What are you working on next?
My next big trial is ORBITA-2 which is currently in the recruitment phase. This will build on the work of ORBITA. It is the next placebo-controlled trial of angioplasty and will test whether PCI improves symptoms in a wider range of patients than those included in the first trial. My main focus at the moment is continuing to understand the link between stenosis, ischaemia, and symptoms in patients with stable coronary artery disease. I have three PhD students working on really interesting studies that will help us to know much more.
As a result of COVID-19, multiple new options for disseminating scientific developments have arisen. By what means do you stay up to date with the latest cutting-edge advancements in cardiology?
I think the challenging last few months have taught us that it is possible to connect globally and to keep learning even without our traditional face-to-face conferences and meetings. The organisers of scientific congresses have worked so hard to find new platforms and new ways to present information digitally. Social media has been an invaluable resource; it means we can have real time interactions with our peers which has certainly improved a stressful experience. Some of this new experience has been fantastic and has allowed us to juggle conference attendance with busy day jobs and our home lives; however, I really miss the old times. Nothing can really replace the ability to chat face-to-face and I am looking forward to the return of the conventional meeting! But I am thankful that we have all been able to support each other across the world; I think that seeing each other again will be all the more precious given what we've all been through.
Within the 14 years of your clinical cardiology career, you have presented at multiple international cardiology conferences worldwide; why do you consider presenting at events to be of importance?
The dissemination of science is absolutely vital to our ability to advance knowledge and change practice. I have presented in all sorts of formats all over the world. Sometimes my audience has been interested in the results and other times they have been less happy to listen. Whatever the situation, I enjoy the challenge of explaining my work to others and the collaborations and future research that creates.
Related To This Subject
Familial Hypercholesterolaemia and the Risk of Eating Disorders
Siesta, Total Sleep Duration, and the Occurrence of Hypertension
Current Evidence on Tobacco Harm Reduction in Pneumology: Interviews with Two Key Opinion Leaders
Interview: Çetin Erol
Effect of Age on the Abdominal Aortic Aneurysm: Fuzzy Logic Analysis
EMJ Cardiology 10 [Supplement 8] 2022
To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Podcast: Gold with Gore
Copyright © 2023 European Medical Group LTD trading as European Medical Journal. All rights reserved. European Medical Journal is for informational purposes and should not be considered medical advice, diagnosis or treatment recommendations.
Ts & Cs Privacy Policy Cookie Policy
Website by Vibe Agency
Proud to be ISO9001 Certified.
The ISO 9001 standard is an internationally recognised standard that is based on a number of quality management principles including a strong customer focus, the management of process change, effective methods of reducing non- compliance, and the continual improvement in the quality of our services.

redpajama_set_name: RedPajamaCommonCrawl


text:
Kings' Regehr leaves in first period, returns for second
By Cam TuckerDec 2, 2013, 11:49 PM EST
The L.A. Kings may have dodged an injury.
Defenseman Robyn Regehr left Monday's game against the St. Louis Blues just past the midway point of the first period, but returned for the second, with an unknown issue, according to Helene Elliott of the L.A. Times.
Regehr's final shift of the opening period finished with 7:14 left to play, but he left briefly to go to the dressing room, although the issue wasn't disclosed.
The 33-year-old blue liner is now up to four assists on the season; he added a helper on Jarret Stoll's goal, which opened the scoring at the 10:38 mark of the first period.
Follow @CamTucker_Metro


Sometimes my heart hurts. It used to be because of my own pain and embracing my own reality. Now my heart hurts for those I have to watch walk paths I have had to walk—spouses who have experienced infidelity or friends who have had to go through the death of a loved one. So many times in the last few years I have wished I could just do it all again—in their place—instead of watching them have to suffer. I see them struggle, and genuinely wish I could save them and take away the hurt.
So tonight I just wanted to share how grateful I am that we have a Savior; that—though we cannot take away another's pain—we know that they can make it through. For it is not our strength that will ease another's burdens and help them find their journey to healing . . . it is Christ.
And every path He leads us down to be His hands, or to see with His eyes, is a gift we get to be apart of. And He has given us each other to physically stand in His place at times. Tonight I am grateful for that miracle. That the Savior of the world will save us all . . . from each other, from the darkness, and even save us from ourselves at times. He is there. ALWAYS. All we have to do is reach out our hand and He will help us take that first step to standing.
So many hurting in a broken world. We cannot save everyone. But Christ can . . . and He already has.


text:
Nov. 13, 2020, 6:06 a.m. EST
10-Q: ACUTUS MEDICAL, INC.
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and related notes and other financial information included elsewhere in this Form 10-Q. Some of the information contained in this discussion and analysis or set forth elsewhere in this Form 10-Q, including information with respect to our plans and strategy for our business, includes "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In some cases, you can identify these statements by forward-looking words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "should," "estimate," or "continue," and similar expressions or variations. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled "Risk Factors" included in this Form 10-Q. The forward-looking statements in this Form 10-Q represent our views as of the date of this Form 10-Q. Except as may be required by law, we assume no obligation to update these forward-looking statements or the reasons that results could differ from these forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Form 10-Q.
We are an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Despite several decades of effort by the incumbents in this field, the clinical and economic challenges associated with arrhythmia treatment continue to be a huge burden for patients, providers and payors. We are committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more effectively and efficiently. Through internal product development, acquisitions and global partnerships, we have established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products. Our goal is to provide our customers with a complete solution for catheter-based treatment of cardiac arrhythmias in each of our geographic markets.
Our product portfolio includes novel access catheters, diagnostic and mapping catheters, ablation catheters, mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Our foundational and most highly differentiated product is our AcQMap imaging and mapping system. Our paradigm-shifting AcQMap System offers a novel approach to mapping the drivers and maintainers of arrhythmias with unmatched speed and precision. With the ability to rapidly and accurately identify ablation targets and to confirm both ablation success and procedural completion, we believe our AcQMap System addresses the primary unmet need in electrophysiology procedures today.
We were incorporated in the State of Delaware on March 25, 2011 and are headquartered in Carlsbad, California. Early versions of our AcQMap System and certain related accessory products have been used in the United States since May 2018 and Western Europe since July 2016 in a limited, pilot launch capacity, where our focus was on optimizing workflow and validating our value proposition. We fully commenced the launch of our commercial-grade console and software products in the first quarter of 2020. Critical to our launch were a series of recent strategic transactions and regulatory approvals, including: FDA 510(k) clearance and CE Mark of our second-generation AcQMap console and SuperMap software suite; the addition of an integrated family of transseptal crossing and steerable introducer systems to our product portfolio through our acquisition of Rhythm Xience, Inc., or Rhythm Xience; and the acquisition of our AcQBlate Force sensing product line from Biotronik SE & Co. KG, or Biotronik. Since our full launch, we have continued to enhance our product portfolio and global presence by entering into bi-lateral distribution agreements with Biotronik in May 2020, which added a full suite of diagnostic and ablation catheters to our product portfolio and significantly expanded our international distribution and market development capabilities.
The diagram below depicts a chronology of these and other key events since our inception:
[[Image Removed]]
We market our electrophysiology products worldwide to hospitals and electrophysiologists that treat patients with arrhythmias. We have strategically developed a direct selling presence in the United States and select markets in Western Europe where cardiac ablation is a standard of care and third-party reimbursement is well-established. In these markets, we install our AcQMap console and workstation with customer accounts and then sell our disposable products to those accounts for use with our system. In other international markets, we leverage our partnership with Biotronik to install our AcQMap console and workstation with customer accounts and then to sell our disposable products to those accounts. Once an AcQMap console and workstation is established in a customer account, our revenue from that account becomes predominantly recurring in nature and derived from the sale of our portfolio of disposable products used with our system. Our currently marketed disposable products include access sheaths, transseptal crossing tools, diagnostic and mapping catheters, ablation catheters and accessories. We plan to leverage the geographically concentrated nature of procedure volumes and the recurring nature of our sales to drive an increasingly efficient commercial model.
As of September 30, 2020, our commercial organization consisted of 62 individuals with substantial applicable medical device, sales and clinical experience, including sales managers, sales representatives and mappers. Over time, we plan to selectively add highly qualified personnel to our commercial organization with a strategic mix of sales representatives and mappers to cover the concentrated group of hospitals that we believe perform the majority of the cardiac ablation procedures in our direct markets.
Our revenue has historically consisted predominantly of sales of our disposable products (principally our mapping catheters and related access sheaths, and to a lesser extent our transseptal crossing tools, ablation catheters and other accessories), as we generally loaned our first-generation AcQMap console and workstation to our customers without charge to facilitate the use of our disposable products. Beginning in late 2019, we began to install our second-generation AcQMap console and workstation with customers under evaluation contracts. Under these evaluation contracts, we place our AcQMap console and workstation with customers for no upfront fee to the customer during the applicable evaluation period and seek to reach agreement with the customer for purchase of the console and workstation in the form of a contractual commitment to purchase a minimum amount of our disposable products or a cash purchase. In addition, we have also generated a small portion of our revenue from service agreements with our customers.
We currently manufacture our novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, ablation catheters, mapping and imaging consoles and accessories at our approximately 50,800 square foot facility in Carlsbad, California. This facility provides approximately 15,750 square feet of space for our production and distribution operations, including manufacturing, quality control and storage. In addition, we stock inventory of raw materials, components and finished goods at our facility in Carlsbad and, to a limited extent, with our sales representatives, who travel to our customers' locations as part of their sales efforts. We rely on a single or limited number of suppliers for certain raw materials and components, and we generally have no long-term supply arrangements with our suppliers, as we generally order on a purchase order basis. Furthermore, we rely on third parties to manufacture certain products we offer our customers as part of our product portfolio, including Biotronik for diagnostic and ablation catheters, radiofrequency, or RF, generators and irrigation pumps, Innovative Health for reprocessed diagnostic catheters and MedFact for robotic navigation enabled ablation catheters.
As of September 30, 2020, we have completed three clinical trials that collectively evaluated 223 subjects across 16 centers in multiple countries. We are currently conducting two post-market trials to provide physicians with additional safety and effectiveness data on the use of our AcQMap System. Global data has been collected on over 100 participants. We are planning two investigational device exemption (IDE) studies to support U.S. regulatory approval of our AcQBlate Force ablation catheters. Our ongoing and planned trials are anticipated to involve an aggregate of over 700 subjects in at least 35 centers in the United States and internationally. We expect to provide data readouts from these ongoing and planned trials at various points in time through early 2024.
For the nine months ended September 30, 2020, and 2019, we generated revenue of $5.9 million and $2.2 million, respectively, of which 46% and 72%, respectively, was from customers located outside of the United States. Since our inception, we have generated significant losses. Our net loss was $72.6 million and $77.1 million for the nine months ended September 30, 2020 and 2019, respectively. As of September 30, 2020 and December 31, 2019, we had an accumulated deficit of $331.6 million and $259.0 million, respectively, and working capital of $159.5 million and $50.5 million, respectively. Prior to our initial public offering ("IPO") on August 10, 2020, our operations have been financed primarily by aggregate net proceeds from the sale of our convertible preferred stock and principal of our converted debt of $253.9 million, as well as other indebtedness.
We intend to continue to make significant investments in our sales and marketing organization. We believe increasing the number of sales representatives and expanding our international marketing programs will help facilitate further adoption of our products among existing customer accounts as well as broaden awareness of our products to new accounts. We also expect to continue to make substantial investments in our ongoing clinical trials and in additional clinical trials that are designed to provide clinical evidence of the safety and effectiveness of our existing and future generations of products. We expect to continue to make investments in research and development and regulatory affairs to develop future generations of products based on our technology, supported with appropriate regulatory submissions. We may in the future seek to acquire or invest in additional businesses, products or technologies that we believe could complement or expand our portfolio, enhance our technical capabilities or otherwise offer growth opportunities. We will also incur costs as a public company that we have not previously incurred or have previously incurred at lower rates, including increased costs for employee-related expenses, director and officer insurance premiums, audit and legal fees, investor relations fees, fees to members of our board of directors and expenses for compliance with public-company reporting requirements under the Exchange Act and rules implemented by the SEC, as well as Nasdaq rules. Because of these and other factors, we expect to continue to incur substantial net losses and negative cash flows from operations for at least the next several years.
Biotronik Agreements
Biotronik License Agreement
In July 2019, we entered into the Biotronik License Agreement with Biotronik and VascoMed GmbH, or VascoMed (who we refer to together as the Biotronik Parties), whereby we acquired certain manufacturing equipment and obtained from the Biotronik Parties a license under certain patents and technology to develop, commercialize, distribute and manufacture our AcQBlate Force ablation catheters and Qubic Force device. We refer to this transaction as the Biotronik Asset Acquisition. Pursuant to the Biotronik License Agreement, we paid Biotronik a $3.0 million upfront fee at the time the agreement was signed, as well as a technology transfer fee consisting of $7.0 million in cash in December 2019 and $5.0 million in shares of our Series D convertible preferred stock in February 2020.
The Biotronik License Agreement also requires that we pay the Biotronik Parties certain milestone payments as follows: (i) $2.0 million upon receipt of marketing approval for the sale of our AcQBlate Force ablation catheters in Europe; (ii) $5.0 million upon the receipt of marketing approval for the sale of our AcQBlate Force ablation catheters in the United States; and (iii) $3.0 million upon the first commercial sale of our AcQBlate Force ablation catheters in the United States. We are also required to pay the Biotronik Parties unit-based royalties on any sales we make of our AcQBlate Force ablation catheters following commercialization.
Bi-Lateral Distribution Agreements
In May 2020, we entered into more expansive bi-lateral distribution agreements with Biotronik. We refer to these agreements as the Bi-Lateral Distribution Agreements and our relationship with Biotronik as the Acutus/Biotronik Global Alliance for Electrophysiology. Pursuant to our Bi-Lateral Distribution Agreements, we obtained a non-exclusive license to distribute a range of Biotronik's therapeutic electrophysiology products and accessories (including the AlCath family of RF ablation catheters) in the United States, Canada, China, Hong Kong and multiple Western European countries under our own private label. Moreover, if an IDE clinical trial is required for these products to obtain regulatory approval in the United States, or a clinical trial is required for these products to obtain regulatory approval in China, we will obtain an exclusive distribution right in such territories for a term of up to five years commencing on the date of regulatory approval if we cover the cost of the IDE or other clinical trial and we conduct such study within a specified period. We also obtained a non-exclusive license to distribute a range of Biotronik's diagnostic electrophysiology products and accessories in each of the foregoing territories under our own private label.
Pursuant to the Bi-Lateral Distribution Agreements, Biotronik has also agreed to distribute our products, including our AcQMap System, our Qubic Force device and our disposable products (including our AcQBlate Force catheters) and accessories in Germany, Japan, Mexico, Switzerland and multiple countries in Asia-Pacific, Eastern Europe, the Middle East and South America. We also granted Biotronik a co-exclusive right to distribute these products in Hong Kong. Biotronik is required to use our branding with respect to the AcQMap console and workstation, but retains the right to distribute our disposable products and accessories under its private label. Each party will pay to the other party specified transfer prices on the sale of the other party's products under the Bi-Lateral Distribution Agreements and, accordingly, will earn a distribution margin on the sale of the other party's products.
Key Business Metric
We regularly review a number of operating and financial metrics, including the following key business metric, to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions. We believe that the following metric is representative of our current business. However, we anticipate this metric may change or may be substituted for additional or different metrics as our business grows and as we introduce new products.
Installed Base
Once an AcQMap console and workstation is established in a customer account, our revenue from that account becomes predominantly recurring in nature and derived from the sale of our portfolio of disposable products used with our system. We believe our installed base is one of the key indicators of our ability to drive customer adoption of our products. We define our installed base as the cumulative number of AcQMap consoles and workstations placed into service at customer sites. Beginning in late 2019, we began to install our second-generation AcQMap console and workstation with customers under evaluation contracts. Under these evaluation contracts, we place our AcQMap console and workstation with customers for no upfront fee to the customer during the applicable evaluation period and seek to reach agreement with the customer for the purchase of the console and workstation in the form of a contractual commitment to purchase a minimum amount of our disposable products or a cash purchase. Our total installed base as of September 30, 2020 and 2019 is set forth in the table below:
2020             2019
Acutus Direct
US                            29              6
Europe                        15             17
Total Acutus Direct           44             23
Biotronik                      5              -
Total installed base          49             23
Our net increase in installed base for the three and nine months ended September 30, 2020 and 2019, exclusive of transfers between Acutus and Biotronik, is set forth in the table below:
Three Months Ended           Nine Months Ended
September 30,                September 30,
2020             2019        2020            2019
(unaudited)                  (unaudited)
US                                    9             (2 )          19             1
Europe                                2             (1 )           3             1
Total Acutus Direct                  11             (3 )          22             2
Net systems to Biotronik              -              -             -             -
Total net system placements          11             (3 )          22             2
Growth in our quarterly installed base can fluctuate due to a number of factors, including the commercial effectiveness of our sales representatives and strategic partners such as Biotronik, and the procurement and budgeting cycles of many of our customers, especially those where unused funds may be forfeited or future budgets may be reduced if purchases are not made by their fiscal year end. We also believe the timing of installations has been impacted and will continue to be impacted by the timing of product introductions and transitions. In addition, the growth of our market in certain geographic regions and our continued efforts to service these regions impact unit volumes quarter to quarter.
Factors Affecting Our Performance
There are a number of factors that have impacted, and we believe will continue to impact, or that we expect to impact, our results of operations and growth. These factors include:
Market Acceptance. The growth of our business will depend substantially on our ability to increase our installed base. Once an AcQMap console and workstation is established in a customer account, our revenue from that account becomes predominantly recurring in nature and derived from the sale of our portfolio of disposable products used with our system. Our ability to increase our installed base will depend on our ability to gain broader acceptance of our AcQMap System by continuing to make physicians and other hospital staff aware of the benefits of the AcQMap System, thereby generating increased demand for system installations and the frequency of use of our disposable products. Although we are attempting to increase our installed base through our established relationships and focused sales efforts, we cannot provide assurance that our efforts will be successful.
Commercial Organization Size and Effectiveness. As of September 30, 2020, our commercial organization consisted of 62 individuals with substantial applicable medical device, sales and clinical experience, including sales managers, sales representatives and mappers. We intend to continue to make significant investments in our commercial organization by increasing the number of our sales representatives, sales managers and mappers, as well as by expanding our global marketing and training programs, to help facilitate further adoption of our products among existing and new customer accounts. The rate at which we grow our commercial organization and the speed at which newly hired personnel become effective can impact our revenue growth or our costs incurred in anticipation of such growth.
Strategic Partnerships and Acquisitions. We have in the past, and may in the future, enter into strategic partnerships and acquire complementary businesses, products or technologies. For example, we have entered into strategic partnerships with Innovative Health and Stereotaxis and, most recently, we entered into our Global Alliance for Electrophysiology with Biotronik in May 2020. In addition, we added an integrated family of transseptal crossing and steerable introducer systems to our product portfolio through our acquisition of Rhythm Xience in June 2019 and acquired our AcQBlate Force sensing product line from Biotronik in July 2019. Our strategic partnerships and acquisitions have helped us establish a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products. Our ability to grow our revenue will depend substantially on our ability to leverage our strategic partnerships and acquisitions to achieve distribution at a global scale, broaden our product portfolio and enable and accelerate global connectivity.
Continued Investment in Innovation. Our business strategy relies significantly on innovation to develop and introduce new products and to differentiate our products from our competitors. For example, in 2019, our research and development team released five new disposable products, two hardware products, including a major generational update to our AcQMap System, and 15 software updates. We expect our research and development expenditures to increase as we make additional investments to support our growth strategies. We plan to increase our research and development expenditures with internal initiatives, as well as potentially licensing or acquiring technology from third parties. We also expect expenditures associated with our manufacturing organization to grow over time as production volume increases and we bring new products to market. Our internal and external investments will be focused on initiatives that we believe will offer the greatest opportunity for growth and profitability. With a significant investment in research and development, a strong focus on innovation and a well-managed innovation process, we believe we can continue to innovate and grow. Introducing additional, innovative products is also expected to help support our existing installed base and help drive demand for additional installations of our system. If, however, our future innovations are not successful in meeting customers' needs or prove to be too costly relative to their perceived benefit, we may not be successful. Moreover, as cost of products sold, operating expenses and capital expenditures fluctuate over time, we may experience short-term, negative impacts to our results of operations and cash flows, but we are undertaking such investments in the belief that they will contribute to long-term growth.
Product and Geographic Mix; Timing. Our financial results, including our gross margins, may fluctuate from period to period due to a variety of factors, including: average selling prices; production volumes; the cost of direct materials; the timing of customer orders or medical procedures and the timing and number of system installations; the number of available selling days in a particular period, which can be impacted by a number of factors such as holidays or days of severe inclement weather in a particular geography; the mix of products sold and the geographic mix of where products are sold; the level of reimbursement available for our products; discounting practices; manufacturing costs; product yields; headcount; and cost-reduction strategies. For example, gross margins on the sale of our products by our direct selling organization in the United States and Western Europe are higher than gross margins on the sale of our products by Biotronik in other parts of the world. Moreover, gross margins on the sale of our proprietary products are generally higher than gross margins on the sale of products we source through our strategic partnerships with third parties. Future selling prices and gross margins for our products may fluctuate due to a variety of other factors, including the introduction by others of competing products or the attempted integration by third parties of capabilities similar to ours into their existing products. We aim to mitigate downward pressure on our selling prices by increasing the value proposition offered by our products through innovation. While we have not yet experienced significant seasonality in our results, it is not uncommon in our industry to experience seasonally weaker revenue during the summer months and end-of-year holiday season.
Regulatory Approvals/Clearances and Timing and Efficiency of New Product Introductions. We are seeking FDA clearance and CE Mark for the use of our AcQBlate Force ablation catheters and Qubic Force device in the United States and Europe, as well as regulatory clearance or approval of our other pipeline products in the United States and in international markets. Our ability to grow our revenue will depend on our obtaining necessary regulatory approvals or clearances for our products. In addition, as we introduce new products, we expect to build our inventory of components and finished goods in advance of sales, which may cause quarterly fluctuations in our results of operations.
Competition. Our industry is intensely competitive, subject to rapid change and significantly affected by new product introductions and other market activities of industry participants. Our most significant competitors are large, well-capitalized companies. We must continue to successfully compete considering our competitors' existing and future products and related pricing and their resources to successfully market to the physicians who could use our products. Publications of clinical results by us, our competitors and other third parties can also have a significant influence on whether, and the degree to which, we are able to gain market share and increase utilization of our products.
COVID-19 Pandemic. Beginning in early March 2020, the COVID-19 pandemic and the measures imposed to contain this pandemic disrupted and are expected to continue to impact our business. For example, on March 19, 2020, the Executive Department of the State of California issued Executive . . .
Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.
(c) 1995-2020 Cybernet Data Systems, Inc. All Rights Reserved


text:
package at.tugraz.sss.serv.datatype.ret;

import at.tugraz.sss.serv.datatype.*;
import at.tugraz.sss.serv.util.*;
import io.swagger.annotations.*;
import java.util.ArrayList;
import java.util.List;

@ApiModel
public class SSEntitiesAccessibleGetRet extends SSServRetI{

  @ApiModelProperty
  public String         pagesID     = null;

  @ApiModelProperty
  public int        pageNumber  = 1;

  @ApiModelProperty
  public int        pageNumbers = 0;

  @ApiModelProperty
  public List<SSEntity> entities    = new ArrayList<>();

  public static SSEntitiesAccessibleGetRet get(
    final List<SSEntity> entities,
    final String         pagesID,
    final int            pageNumber,
    final int            pageNumbers){

    return new SSEntitiesAccessibleGetRet(entities, pagesID, pageNumber, pageNumbers);
  }

  public SSEntitiesAccessibleGetRet(){/* Do nothing because of only JSON Jackson needs this */ }

  private SSEntitiesAccessibleGetRet(
    final List<SSEntity> entities,
    final String         pagesID,
    final int            pageNumber,
    final int            pageNumbers){

    super(SSVarNames.entitiesAccessibleGet);

    SSEntity.addEntitiesDistinctWithoutNull(this.entities, entities);

    this.pagesID     = pagesID;
    this.pageNumber  = pageNumber;
    this.pageNumbers = pageNumbers;
  }
}

redpajama_set_name: RedPajamaGithub


Our enterprise since its inception, usually regards product top quality as business life, repeatedly enhance manufacturing technology, make improvements to product excellent and continuously strengthen enterprise total high quality administration, in strict accordance with all the national standard ISO 9001:2000 for Spring Loaded Check Valve , Spring Loaded Disc Check Valve , Spring Check Valve , and create a dazzling long run jointly.
"Our solutions are broadly acknowledged and trustworthy by end users and might meet up with consistently transforming economic and social needs of Spring Loaded Check Valve , Spring Loaded Disc Check Valve , Spring Check Valve , Custom orders are acceptable with different quality grade and customer's especial design. We are looking forward to establish the good and successful cooperation in business with long terms from the customers of all over the world.


text:
Affordable Care Act: more costly than ever
Published 4:32 pm Wednesday, November 2, 2016
By Robert Hurt
Last week, the Obama administration confirmed that the Affordable Care Act continues to break one of its signature promises — that the law would in fact reduce the cost of health care for the American people. The administration announced that insurance premiums in the federally-managed health exchanges would increase by an average of 25 percent for the mid-level benchmark plan in 2017.
We have seen these costs grow in recent years, so this news is no surprise, nor was it unforeseeable when the law was debated and passed. We knew that government-knows-best rules and mandates would not in fact make health care less expensive nor achieve many of the other things the proponents promised.
The Richmond Times-Dispatch reported that Virginia consumers will fare "relatively well" as it relates to these increases, and on a statistical basis that is certainly accurate. On average, Virginians will see a 10 percent premium increase for benchmark plans and an overall 19.5 percent average premium increase for all plans, far less than the 53 percent increase in Pennsylvania, or the 63 percent hike in Tennessee, or the staggering 116 percent jump in premiums in Arizona. But Fifth District Virginians would not describe 10-20 percent increases as faring well because they cannot afford double-digit hikes at a time when the economy is not growing fast enough nor are good jobs and wages.
In response to critics of these premium hikes, defenders of the law point out that most of the exchange participants receive government subsidies that will offset some of the increased costs.
But that is also cause for great concern because hardworking American taxpayers are paying and will continue to face higher taxes to pay these subsidies and our debt will increase more rapidly as these costs continue to spiral out of control.
This is an entirely unsustainable course.
Additionally, insurer participation in the exchanges will decrease dramatically next year, with 70 companies stating they will no longer offer coverage.
As a result, nearly 20 percent of exchange participants will only have one insurer available to them.
Absent choice and competition, it is no surprise costs are increasing. And consumers are also being forced to see new doctors and health care providers given these changes, representing yet another broken promise.
Perhaps the most unfortunate fact is that we have known from the very beginning these outcomes were both likely and foreseeable, yet we have been led down this path and the American people are suffering the consequences. They have seen billions of dollars in tax money spent, higher out of pocket costs for consumers, loss of access to preferred coverage and providers, fewer jobs and fewer work hours, yet none of the promises of the law have been fulfilled.
It is time to reverse course and put an end to the broken promises.
We must inject market-oriented reform into the healthcare system that gives the American people more choice and will reduce their costs.
Making care more affordable will increase access for everyone while enabling them to see the doctors of their choosing.
I remain committed to reforms that are patient-centered and market-oriented to deliver the healthcare system the American people deserve.
Robert Hurt represents Charlotte County in the U.S. House of Representatives. He can be reached in his Farmville office at (434) 395-0120.
Frank Ruff: Off to the races
Mike Wilson: Attack of the Identified Flying Objects
Frank Ruff: Big issues in 2023 General Assembly
Mike Wilson: I sympathized with Rodney Dangerfield


the person wearing it and in a figurative sense it stands for beauty – power – love – honor – affection – religion and much more.
The formal possibilities of jewelry design are virtually endless.
But the idea and design are not everything. Jewelry must be able to be worn comfortable and adapt to the body. This is an exciting task for the goldsmith, a ladies necklace or a gentleman`s signet ring.
Choose something from the extensive range of our business or evolve together with us exactly the piece of jewelry that suits your ideas and wishes.
We apply extraordinary jewels to rings, pendants and ear jewelry, from aquamarine to ruby, emerald, topaz and zircon. But also diamond and pearl jewelry worked in white gold, yellow gold, pink gold or rosé gold as well as platinum and fine silver we produce for you.
Professional advice and craftsmanship that sets few limits are part of our self-understanding.


A man who is discerning a vocation to the priesthood will eventually come to understand that discernment cannont proceed any further oustide of seminary. The decision to enter seminary is an important part of discernment where a man is able to continue to discern wheter God is calling him to priesthood with the support of formators, spiritual directors, and other smenarians.
Learn more about the process of becoming a seminarian, seminary formation, answers to common questions, and opportunities to learn more about priesthood by contacting Our Vocation Team!
Meet our current Diocese of Brownsville seminarians to learn more about discerning a vocation to priesthood and seminary life!


Pre-war, it was Syria's largest city and commercial hub. Hundreds of thousands fled the fighting. US backed terrorists committed massacres, gruesome atrocities and vast destruction. Syrians vow to rebuild the city after liberating it, including restoring damaged archeological sites.
Aleppo, widespread destruction at the hands of US-spawned and supported lunatics.
A joint Syrian military/Russian aerial forces offensive is being prepared similar to Palmyra's liberation. More on this below.
"A considerable part of the territory is under control of the pro-government force." Thirty km of territory around liberated Al-Qaryatayn are controlled by government forces.
"(H)undreds of times more such territories" were liberated since 2015. Things are "gaining momentum." Syrians hope for liberating the entire country from terrorists.
Latakia province and most parts of Hama and Homs were retaken. Vast areas are back in government hands, advancing Syrian military forces greatly aided by Russian air power and intelligence continue routing ISIS and other terrorists.
According to Syrian Prime Minister Wael al-Halaki, "(w)e, together with our Russian partners, are preparing for an operation to liberate Aleppo and block all illegal armed groups which have not joined the ceasefire deal or violated it" – retaking Deir Ezzor to follow.
Russian intelligence reported over 1,000 heavily armed Jabhat al-Nusra fighters concentrated north of Aleppo in Muheimhandrat, Jandul, Hraitan and Qafr-Hamra. A major joint Syrian/Russian operation intends liberating them from its scourge.
The Spectacularly Insane World of Right-Wing Conspiracy Theories and Who is Really Behind Them!


text:
Thought | Sunday, August 21, 2022 | 0 Comments
Pointless Viewpoint Characters
So, okay, Sega is apparently developing films based on two of its classic titles: rhythm game Space Channel 5 and beat 'em up Comix Zone. Which–okay, cool, whatever; this early it's impossible to say whether they will be any good. (Though my immediate thought was "Okay, now do Crazy Taxi.")
But here's what caught my attention: the Space Channel 5 film will apparently "tell the story of a hapless fast-food worker who is recruited by a freedom reporter from the future to save the world from aliens using the one thing that unites all people on the planet: our love of silly viral dances." If you aren't familiar with the source material: the game Space Channel 5 stars a future reporter saving the world from aliens through dance. There's no "hapless fast-food worker" in the mix. That's new for the film.
To be clear: I'm not trying to pick on this film in particular. This is a really common pattern. The Sonic the Hedgehog games (and comics, and I think mostly the shows) are about Sonic fighting Eggman, while the films are about James Marsden meeting Sonic and helping him fight Eggman. The Transformers cartoons (and comics, and old movies) are about good and evil transforming robots, while the Michael Bay films are about Shia LaBeouf meeting good transforming robots and helping them fight evil transforming robots. And on and on; you get the idea. As part of an attempt to give an adaptation of a niche property more mainstream appeal, the studio adds in what TVTropes calls a "lead you can relate to". As if the audience can't understand a fantastical setting unlike modern Earth or relate to any of its characters unless there's a wholly non-fantastical person along for the ride to comment on how unlike modern Earth this all is (and probably end up playing a key role in saving the day despite being wholly unqualified compared to the setting's preexisting characters).
(Note that this is unnecessary for the Comix Zone adaptation since that game was already about a normal artist getting sucked into the world of their comic; the movie can just do the same thing there with no problem.)
Now, I have to assume from the sheer number of times this has been done and the unimaginable amount of money involved that the strategy works more than it fails (or at least seems to). But it perplexes me. Of course it feels bizarrely patronizing–the source material didn't need to have an everyman audience surrogate in order for the audience to know how to understand and react to the premise and setting. The audience just had their own actual reaction.
But beyond that, naively it seems like this sort of move should reduce the overall appeal of the adaptation.
For the existing fans, the new viewpoint character is an extra layer of metaphor distancing them from what they came for. They're here to enjoy retro-futurist dancers / brightly-colored forest animals / transforming robot battles, not to watch someone else enjoy them. Any time or focus the film spends on the normal everyday person is worse than useless because it takes away from the time or focus spent on what makes this IP what it is and the reasons the fan enjoys it.
So presumably the idea is that having a "more relatable" lead character will gain you more mainstream appeal than it costs you in niche appeal, but like… having a generic protagonist is not a unique selling point, by definition! All it does is make the movie more interchangeable with other movies, and there are so many movies out there–if you're someone who needs that "relatable" lead, are you even going to choose to watch Space Channel 5 instead of an actually-mainstream film in the first place? Why would you, unless the fantastical setting appealed to you? In which case, do you even need the "relatable" lead?
It doesn't make sense to me. It really seems like this kind of adaptation just waters down what sets the source material apart; taking away some of the reason to watch it in particular, replacing it with weaker generic appeal that makes it stand out less.
I can see where that's a good approach if there aren't many choices available to the audience and you just need to avoid pushing people away and thus remove reasons not to watch your film. But given the options available to modern film audiences, I'd expect you to be better off giving people a clear reason to watch your film by offering something other films do not.
#space channel 5 #comix zone #sega #video game movies #sonic the hedgehog
Tags: Thought, GAME: Space Channel 5, GAME: Comix Zone, TOPIC: Marketing
⇐ PREVIOUS THOUGHT: Like rocking a bicycle ⇒ NEXT THOUGHT: Star Trek (2013-2016)
[THOUGHT] First Eleven's Free
[THOUGHT] Persona 5 Action, not Persona 5 Musou
[THOUGHT] Black Hole Stunt
[THOUGHT] Apple Arcade and Gateway Games
[THOUGHT] I'd Buy That for a Dollar


text:
Review >> Action Camera, a new trend when it is necessary to drop a camera but great photos are still wanted. written by น้ำ-ฟ้า-ป่า-เขา
It's time that a cameraman has a hunger for adventure and fun life. And it's a must to leave a professional camera behind but still cool photos are wanted. The result is...!!! A chill out trip to have fun at Thongsomboon Club, Pak Chong District With A Great Action Cam
Review >> Action Camera, a new trend when it is necessary to drop a camera but great photos are still wanted.
Thursday, October 15, 2015 8:49 PM
น้ำ-ฟ้า-ป่า-เขา
kao yai
It's time that a cameraman has a hunger for adventure and fun life.
And it's a must to leave a professional camera behind but still cool photos are wanted.
The result is...!!!
A chill out trip to have fun at Thongsomboon Club, Pak Chong District
A Great Action Camera Panasonic HX-A1
From Saraburi Province, we turn right and head to Pak Chong District about 66 kilometres then we arrive at the adventure land.
GPS Coordinates of Thongsomboon Club: 14.729838, 101.391376
Finally we arrive in Thongsomboon Club and we head to the Adventure Zone immediately.
There is no admission fee but the round trip shuttle service to the Adventure Zone costs 50 baht. To walk is about 2 kilometers. I don't recommend at all, as it's so hot and sunny.
Alright, we are so ready, we drop a professional camera and take a new Action Camera with stylish look similar to a small flashlight. Its colour is orange like a kind of orange that use to make a sacrifice to gods among the Chinese. Richer and wealthier!!
We are ready to go! Please follow. There are more than 10 types of playthings, which cost the same at 150 baht each. If you buy 5 tickets, you will get 1 ticket for free.
Those yellow circles mean we have played already. We are 2 people and we buy 10 tickets so we get 2 tickets for free haha.
It is similar to hill tribe racing cart, which has no engine. It counts on gravity to move along the slopes of the mountain. Photos are wanted so what should we do. We have this Panasonic HX-A1.
We stick it in the middle of handlebars.
To enjoy in the air with
I stick the camera in one ear and quickly go. I have both fun and impressive photos. (I will put them in a short clip at the end of this review).
After playing Luge and Flying Fox, we take a free chairlift back to the starting point. However, it is chargeable and count as one type of plaything if you want to take a chairlift forwards and backwards.
Let's continue. It's super fun. There are not many people on weekday and this means we don't have to queue up^^.
Log Ride
The Log Ride is a great fun with water splashing. There is no need to worry about Panasonic HX-A1 because it's waterproof camera without wearing any covers. Let's go!
Racing ATV
An all-terrain vehicle (ATV) or a four wheel bike. We drive this through the given directions about one and a half kilometers distance.
What a great fun!!!
Next to the ATV racing field, it is a Go Cart station, a four-wheel low loader kart. We don't have enough time to play this because there is another racing plaything nearby, which is...
Buggy Ride
A four wheel, two seat buggy. It requires two people with two tickets. Although you want to go through this fun alone, you still need to have two tickets. It's count by buggy.
We attach Panasonic HX-A1 camera at the rear of the buggy to shoot through the dust. Again, there is no need to worry, as it's a dust-proof camera. Wow!
We look at the time. It is already five o'clock. Just about run out of time while there are still four tickets left. What to do? At first we are to pay BB Gun but we afraid that we can't make it on time. However, staff tells us that there is something available.
It is at the outside zone (somewhere at the parking). It's a laser gun and there is a photo studio to wear cowboy outfit and take photos. Oh! It's quite interesting thus we agree with the staff. The shuttle service is called to take us to outside. We use the same ticket that we buy before at 50 baht for this ride.
The sun light is so beautiful, thus the staff is so kind to start up the buggy engine again, drive out and park it for us to shoot a few photos while we are waiting. At this point, I take my mobile out and open Panasonic Image Application that I already downloaded to be a remote screen. Then I adjust the camera mode to still image.
Click , click and click about two to three times. I have such a pretty model with a scarf on, she looks like a young cowboy girl in this portrait.
The still image mode on this camera can be adjusted to only two modes. These are a normal frame at 120° angle of view and a wide frame at 150° angle of view. Super wide!!
Shuttle service is delayed! We almost can't play anything. The Photo Studio is close so my girl can't have the cowboy outfit on and take photos hahaha.
However, laser tag station is still open for us to play. // It's almost close as well.
Staff explains how to play, how to aim and how to shoot. The mission is to win over the enemy. The room is almost completely dark. Only fluorescent screen such as walk way and LED lighting on outfit can be seen.
I am told that there will be infrared light to help in aiming to shoot. Once, I know this I change the camera to the mode of O LUX ... Night Mode and take it with me to record the excited scene inside. I am really satisfied.
It's already 6 o'clock in the evening. Time is over with half day trip on a normal weekday but very special. It's full of fun and many memorable photos.
On the way back to Bangkok, we find a restaurant to eat, see the photos and watch the clips through application then share to social medias.
Here you can watch a great 3 minute clip.
Thank you to Panasonic in providing this product to be tested for using during this trip.^^/
2 Feet Stop at Mount KINABALU Peak!
By น้ำ-ฟ้า-ป่า-เขา
Prepared and get ready before climbing Mt.Fuji
10 Photo points around Koh Mak ( Koh Mak Castaway Final Episode)
3 interesting things to see at Phu Nang National Park


text:
Repsol Honda Team hunt home glory in Barcelona
With the lead in the Rider and Constructor World Championships in hand, the Repsol Honda Team arrives in Barcelona ready to fight. After a scintillating Italian GP, the Repsol Honda Team enters the Catalan GP with renewed vigour after narrowly missing out on victory in Mugello. Both Marc Marquez and Jorge Lorenzo are looking forward […]
David Johnson takes sensational Superstock podium in packed TT day
Honda Racing's David Johnson took his first Isle of Man TT podium in sensational fashion in today's Superstock race, getting the better of Michael Dunlop by just 0.2seconds. With the weather finally giving an uninterrupted day of running, it was a bumper day of track activity on the Island today. Getting off to a steady start in the Superstock, Davo was eighth on the first of the three-lap race, but wasted no time in starting his ascent through the field. By Ramsey he was sixth, and by the…
Summer Savings - Get €1000 off the CRF450L
Summer has landed....and so have our summer offers! Kicking us off is €1000 off our Honda CRF450L Honda CRF450L was €11,500, it's now €10,500 Save on this fun loving machine until July 31st 2019 The CRF450L mixes its competition-bred performance DNA with full road legality and reliability. And is a helmet-full of fun wherever you ride it. The CRF450L looks like the CRF450R for a reason. It is a CRF450R. Same aluminium beam frame, 449cc Unicam engine and Showa suspension. We've turned it…
Marquez fights fiercely for Italian GP second, Lorenzo grabs more points
Just 0.043s separated Marc Marquez from victory at an explosive Italian GP as his Repsol Honda Team teammate Jorge Lorenzo collected more world championship points. The hottest conditions of the weekend, the track at almost 50°C, awaited the MotoGP World Championship as they 23-rider field lined up for the Gran Premio d'Italia Oakley. From a record-breaking pole position, Marc Marquez made a perfect launch to lead from fellow Honda rider Cal Crutchlow. A race-long battle for victory saw…
Dominant Marquez takes Honda's 300th premier class win in France
Marc Marquez took his third win of the 2019 season with another dominating performance as teammate Jorge Lorenzo took his best finish of the season with 11th. Cold conditions from morning Warm Up carried through until the start of the French Grand Prix at 14:00 local time, a track temperature of just 18°C made for treacherous opening laps. Marc Marquez was able to keep clear of trouble to open a small advantage, Jack Miller the only rider able to stay with him. Miller was briefly able to get…
Dakar 2020: New information
A new chapter in the Dakar Rally story has opened with the official presentation of the 2020 edition due to take place in Saudi Arabia. After Africa and South America, the Middle East now takes up the baton of the rally-raid race par excellence. New details were unveiled yesterday in Paris. With an audience crowded with future participants and various team leaders, the Dakar 2020 Race Director, David Castera outlined more details of the race which was first presented in Saudi Arabia a month ago.…
Honda Racing raring to get roads campaign underway at the International North West 200
Honda is ready to get its 2019 road racing campaign underway as Ian Hutchinson and new recruit, David Johnson, have arrived at the International North West 200 ready to kick off proceedings tomorrow. Wrapping up pre-season testing on a high, the Honda Racing team has enjoyed vast amounts of track time across the off-season in Europe, as well as various UK circuits, including the team's favourite; Castle Combe in Wiltshire, in preparation for the NW200, the Isle of Man TT and the Ulster GP.…
Post race testing at Jerez
The post-race Jerez Test gave Marc Marquez and Jorge Lorenzo a chance to explore a number of potential setup options and development parts for the Honda RC213V. After claiming his second win of the 2019 season, Marc Marquez and the Repsol Honda Team immediately got back to work at the Circuito de Jerez – Angel Nieto. First on the list to test was the development Honda RC213V ridden by Stefan Bradl during the weekend. Setting a 1'37.260, Marquez leaves Jerez seventh fastest in the test. For…
Marquez takes a victory at Jerez!
Marc Marquez becomes first repeat premier class winner of 2019 as he storms to victory in Jerez, Jorge Lorenzo returning to the points. Fans flooded the Circuito de Jerez – Angel Nieto from early in the morning, eager to see what would happen at the Gran Premio Red Bull de España. 21°C ambient temperatures and 42°C track temperature providing supreme racing conditions for fans and the Repsol Honda Team alike. Leaving the fall of Warm Up behind him, Marc Marquez stormed off the line to…
Jerez awaits resurgent Repsol Honda Team
Marc Marquez and Jorge Lorenzo are ready to resume their challenge on Spanish soil as 300th MotoGP race looms. The MotoGP World Championship touches down in Europe for the first time in 2019, the Spanish GP marking the 300th MotoGP race after the class was introduced in 2002. Honda machines have taken 142 wins in that time and both Marc Marquez and Jorge Lorenzo will be fighting to make it 143 in Jerez. After the difficulties of Austin, Marc Marquez arrives in Jerez aiming to get his title…


WASHINGTON - Just add water and stir. A US company says its new powdered alcohol product has been approved by US regulators and is poised to hit stores in the coming months.
Palcohol is made by an Arizona company called Lipsmark and will come in six varieties of single-drink pouches, the company website says.
The company said it was taken by surprise by the recent release of some of its labels by the Alcohol and Tobacco Tax and Trade Bureau, which "actually approved it some time ago". The company said the product will be sold to people of legal drinking age and could even be sprinkled on food.
In response to consumer inquiries about whether the product could be snorted, the company described the askers as "goofballs" and said it would take a half cup of powder to equal one drink.
"Don't do it! It is not a responsible or smart way to use the product," it urged.
Powdered alcohol has already been approved for sale in Japan and some European countries.


text:
The cookie policy employed by our web site and the cookies which we use for analytical purposes are outlined here.
This Cookies Policy sets out the basis on which we, Kumo trading as TWDG Limited, use cookies and similar technologies on or in relation to our website, https://www.kumodigital.co.uk (our website). This Cookies Policy is effective from 22nd May 2018.
'Essential' cookies are automatically placed on your computer or device when you access our website or take certain actions on our website. 'Non-essential' cookies and other technologies are only placed on your computer or device if you have consented to us doing so. For information on the difference between essential and non-essential cookies, see the section below entitled About cookies.
For information on how you consent and how you can withdraw your consent to us placing non-essential cookies and other technologies on your computer or device, see the section below entitled How to accept or reject cookies.
Copyright, credit and logo
If you require further information about cookies in general, please visit www.allaboutcookies.org.
We use the following cookies on or in relation to our website:
Name of Cookie Category Essential or Non-essential? Type of cookie First or Third party? Provider Session or Persistent? Expiry Time Purpose
CookieConsent Necessary Essential HTTP First kumodigital.co.uk Persistent 1 year Stores the user's cookie consent state for the current domain.
lang Preferences Non-essential HTTP Third party cdn.syndication.twimg.com Session Session Remembers the user's selected language version of a website.
_ga Statistics Non-essential HTTP Third party gstatic.com Persistent 2 years Registers a unique ID that is used to generate statistical data on how the visitor uses the website.
_ga Statistics Non-essential HTTP First party kumodigital.co.uk Persistent 2 years Registers a unique ID that is used to generate statistical data on how the visitor uses the website.
_gat Statistics Non-essential HTTP Third party gstatic.com Session Session Used by Google Analytics to throttle request rate.
_gat Statistics Non-essential HTTP First party kumodigital.co.uk Session Session Used by Google Analytics to throttle request rate.
_gid Statistics Non-essential HTTP Third party gstatic.com Session Session Registers a unique ID that is used to generate statistical data on how the visitor uses the website.
_gid Statistics Non-essential HTTP First party kumodigital.co.uk Session Session Registers a unique ID that is used to generate statistical data on how the visitor uses the website.
collect Marketing Non-essential Pixel Third party google-analytics.com Session Session Used to send data to Google Analytics about the visitors device and behavious. Tracks the visitor across devices and marketing channels.
GPS Marketing Non-essential HTTP Third party youtube.com	 Session Session Registers a unique ID on mobile devices to enable tracking based on geographical GPS location.
i/jot Marketing Non-essential Pixel Third party twitter.com Session Session Unclassified
i/jot/syndication Marketing Non-essential Pixel Third party twitter.com Session Session Unclassified
NID Marketing Non-essential HTTP Third party google.com Persistent 6 months Registers a unique ID that identifies a returning users device. The ID is used for targeted ads.
PREF Marketing Non-essential HTTP Third party youtube.com Persistent 8 months Registers a unique ID that is used by Google to keep statistics of how the visitor uses YouTube videos across different websites.
VISITor_INFO1_LIVE Marketing Non-essential HTTP Third party youtube.com Persistent 179 days Tries to estimate the users bandwidth on pages with integrated YouTube videos.
YSC Marketing Non-essential HTTP Third party youtube.com Session Session Registers a unique ID to keep statistics of what videos from YouTube the user has seen.
first party or third party persistent cookies to recognise whether you have accepted the use of cookies on our website. These cookies are: CookieConsent. These cookies expire after 1 year.
For more detailed information on how to accept and reject cookies, including guidance for specific browsers, please see the section below entitled How to accept or reject cookies.
Targeting (or advertising) cookies
first party or third party session cookies to remember the language in which to display our website to you. These cookies are: lang. These cookies expire after users session ends.
See the section below entitled How to accept or reject cookies.
Legal basis for processing: we process information about you contained in or obtained from functional cookies in our legitimate interests (Article 6(1)(f) of the General Data Protection Regulation). We will only process such personal information if you have consented to us placing cookies on your computer or device.
Legitimate interests: improving your website experience and providing or enhancing the website functionality you have requested.
For further information on how we use the information gathered from our use of functional cookies, please see the section entitled Our use of automated decision making and profiling in our privacy policy, which is available here: https://www.kumodigital.co.uk/privacy-policy/.
We use Google Analytics cookies on our website. Google Analytics cookies help us understand how you engage and interact with our website, including how you came to our website, which pages you visited, for how long and what you clicked on, your location (based on your IP address).
The Google Analytics cookies used on our website are: _ga, _gat, _gid. These cookies are session and persistent cookies. These cookies expire after 2 years, session, session respectively.
Google Analytics cookies are classified as first party cookies as they are set by our website domain, although Google collects and processes information from our use of Google Analytics. To find out more about how Google handles information collected from Google Analytics, see Google Analytics' privacy policy, which is available here: https://support.google.com/analytics/answer/6004245.
For information on how Google uses data from cookies it uses, please visit www.google.com/policies/privacy/partners/.
To opt out of Google Analytics tracking across all websites in general, you can do so here: http://tools.google.com/dlpage/gaoptout.
Legal basis for processing: we process information about you contained in or obtained from analytical cookies in our legitimate interests (Article 6(1)(f) of the General Data Protection Regulation).
Legitimate interests: analysing how individuals use our website to help us improve our website and business. For further information on how we use the information gathered from our use of analytical cookies, including profiling, please see the section entitled Our use of automated decision making and profiling in our privacy policy, which is available here: https://www.kumodigital.co.uk/privacy-policy/.
For information on third party targeting or advertising cookies we use on our website, please see the section below entitled Third party cookies.
Third parties use cookies to analyse your use of our website and/or to display advertisements (including third party advertisements) to you and advertisement conversion tracking, behaviour tracking and device useage tracking for platforms such as Google, Google AdWords and YouTube. Third party cookies used in relation to our website include:
Third party advertisement cookies. Google, Google AdWords and YouTube use cookies to display advertisements to you on other websites or based on your interests and behaviour and to measure their effectiveness. You can find out how Google, Google AdWords and YouTube use your information and how they use cookies by accessing their privacy policy at: https://policies.google.com/privacy?hl=en&gl=uk and their cookies policy at: https://policies.google.com/technologies/cookies. These cookies are: NID, PREF, VISITor_INFO1_LIVE, GPS. These cookies expire after 6 months, 8 months, 179 days and session respectively.
Google AdWords cookies to track whether you have come to us via an advertisement we have placed on a search engine results page or elsewhere across the internet, such as another website and to record information relating to how you came to us such as your location when you accessed our website, the time of day you visited and the device you were using and AdWords tracking / conversion cookies. Google may use different cookies to track how you came to our website depending on what advertisement you clicked on and where.
Google remarketing cookies to display advertisements to you about our goods and services across the internet, including on other websites you visit. Google uses cookies to display advertisements to you about our products and services on other websites and locations across the internet based on the fact that you have visited our website. Google may also display other advertisements across the internet to you about third party services using the Google AdSense network, although this is beyond our control. For more information about Google remarketing, click here: https://support.google.com/adwords/answer/2453998?hl=en.
For information about the cookies Google uses in relation to the above, see the 'Advertising' section on the Types of cookies used by Google page in Google's cookies policy, which is available here: https://www.google.com/policies/technologies/types/.
For information about how Google uses data from cookies for its own purposes, please visit the following link www.google.com/policies/privacy/partners/.
How to opt in or out from third party cookies
Processing information about you contained in or obtained from third party cookies
Legal basis for processing: we process information about you contained in or obtained from third party cookies in our legitimate interests (Article 6(1)(f) of the General Data Protection Regulation).
Legitimate interests: the purposes for which we use the third party cookies as described above. For further information on how we use the information gathered from our use of third party cookies, including automated decision making and profiling, please see the section entitled Our use of automated decision making and profiling in our privacy policy, which is available here: https://www.kumodigital.co.uk/privacy-policy/.
Legal basis for processing: consent (Article 6(1)(a) of the General Data Protection Regulation).
Consent: you give your consent to the purposes for which we process your information using third party cookies by utilising our websites cookie consent tool to accept all cookies, specific groups / types of cookies or individual cookies. For further information on how we use the information gathered from our use of third party cookies, including automated decision making and profiling please see the section entitled Our use of automated decision making and profiling in our privacy policy, which is available here: https://www.kumodigital.co.uk/privacy-policy/.
We and any marketing companies we use also embed web beacons in our marketing emails and/or on our website. Web beacons are small GIF image files which enable us to track your receipt of our marketing emails, how often you view our adverts or website pages, your location, IP address and browser information. Web beacons are activated whenever you open a marketing email or access a page on our website which contains a web beacon. Web beacons transmit data when you view them but are not capable of accessing any other information on your computer. Web beacons are not stored on your hard drive unless you download a GIF image containing them.
Some (but not all) browsers enable you to restrict the use of web beacons by either preventing them from sending information back to their source (for example, when you choose browser settings that block cookies and trackers), or by not accessing the images containing them (for example, if you select a 'do not display images (in emails)' setting in your email server). We use the web beacons on our website:
first party or third party web beacons send data to platforms regarding the users device behaviour and tracking visitors across devices and marketing channels. These cookies are: collect, i/jot, i/jot/syndication. These cookies expire after the users session ends.
How to opt in or out
Legal basis for processing: we process the information we gather from the use of web beacons in our legitimate interests (Article 6(1)(f) of the General Data Protection Regulation).
Legitimate interest: analysing the effectiveness of our email marketing campaigns and for other platform embeds to track device behaviour. For further information on how we use the information gathered from our use of web beacons, including automated decision making and profiling please see the section entitled Our use of automated decision making and profiling in our privacy policy, which is available here: https://www.kumodigital.co.uk/privacy-policy/.
There are a number of different ways in which you can accept or reject some or all cookies and similar technologies . Some of the main methods of doing so are described below:
You can find more detailed information about cookies and adjusting your browser settings by visiting www.allaboutcookies.org.
Cookie control tool
You can accept or reject non-essential cookies by using our cookie management tool. The cookie management tool will be displayed at the bottom of our website with checkboxes for enabling / disabling various categories of and individual cookies.
Google Adsettings
You can manage and opt out of personalisation of advertisements by Google by visiting Google's ad settings page here https://adssettings.google.com/ and by:
unticking the button entitled 'Also use Google Account activity and information to personalize ads on these websites and apps and store that data in your Google Account'; and
switching the 'Ads Personalisation' setting off (i.e. by ensuring the switch at the top of the page is set to the left/grey and not the right/blue).
Alternatively, you can install a free browser plugin here: https://support.google.com/ads/answer/7395996.
You can opt out of Google Analytics tracking by installing the browser add-on which is available here: http://tools.google.com/dlpage/gaoptout.
You can opt in to us using web beacons on our website by: utilising our websites cookie consent tool to accept all cookies, specific groups / types of cookies or individual cookies.
You can opt out of our use of web beacons on our website by: utilising our websites cookie consent tool to accept all cookies, specific groups / types of cookies or individual cookies.
European Interactive Digital Advertising Alliance Tool
You can opt out of Facebook and other companies that participate in the Digital Advertising Alliance in Europe from showing you interest based ads by visiting http://www.youronlinechoices.com, selecting your country, clicking 'Your Ad Choices', then locating Facebook (and any other companies you want to block) and selecting the 'Off' option.
This Cookies Policy is based on a template provided by GDPR Privacy Policy.
The copyright in this Cookies Policy is either owned by, or licensed to, us and is protected by copyright laws around the world and copyright protection software. All intellectual property rights in this document are reserved. Where we display the GDPR Privacy Policy logo on our website, this is used to indicate that we have adopted a privacy policy template provided by GDPR Privacy Policy as the basis for this Privacy Policy.
Company Number: 07865143 | Company VAT: 177073296
User Content Agreement |
Copyright © 2022 Kumo trading as TWDG Ltd.


text:
For the best experience
use the MrOwl App
Mobile Title
"<" or ">" are not allowed
Enter username for account
Create Branch
Top Branches
What is MrOwl
Community General Reference Libraries
MrOwl Community
Historical and contemporary collections of books and documents. Includes community and public libraries as well as college/university collections, government libraries, special collections and digital libraries. Includes topics of interest to library patrons and Friends of the Library.
College and University
Government Libraries
National Libraries
Organizational Systems
Presidential Libraries
15 Things You Didn't Know You Could Get From the Library - US News
You can borrow a lot more than the latest thriller or romance novel.
http://money.usnews.com/money/blogs/my-money/2014/07/16/15-things-you-didnt-know-you-could-get-from-the-library
25 Coolest Things About Library of Congress
The Library of Congress is a name that most people recognize, but beyond that it's possible that you may not know that much about the institution and what it does.
http://librarysciencelist.com/25-coolest-things-about-library-of-congress/
11 of the Very Best Things About Libraries - Bustle
11 of the very best things about libraries from Bustle.
http://www.bustle.com/articles/51058-11-of-the-very-best-things-about-libraries-besides-the-books
Reasons to Visit the Library - About
A library is the grand place where books live. For those that love reading and collecting literature, a library can be a magical place of the imagination. It's a great place to find volumes on almost every imaginable topic.
http://classiclit.about.com/od/litlibraries/tp/aa_reasonlibra.htm
5 Good Reasons to Take Your Kids to the Library Today - Huffington Post
Some say that the children's rooms of libraries are an anachronism in a world of mobile screens with books on demand. But I say that while childhood has changed quite a bit, children have not.
http://www.huffingtonpost.com/christine-french-cully/five-good-reasons-to-take_b_5134342.html
The History of Libraries Through the Ages
Libraries have a reputation for being oh-so-boring places you visit only when you absolutely must.
http://www.zencollegelife.com/the-history-of-libraries-through-the-ages/
History of libraries - Wikipedia, the free encyclopedia
The history of libraries began with the first efforts to organize collections of documents.
https://en.wikipedia.org/wiki/History_of_libraries
62 of the World's Most Beautiful Libraries - Mental Floss
For the last couple years, Jill Harness has been rounding up the world's most beautiful libraries by continent. Here they are all in one place, in no particular order.
http://mentalfloss.com/article/51788/62-worlds-most-beautiful-libraries
25 Most Famous Libraries Of The World - Library Science List
The 25 most famous libraries in the world from Library Science List.
http://librarysciencelist.com/25-most-famous-libraries-of-the-world/
Library - Wikipedia, the free encyclopedia
A library is a collection of sources of information and similar resources, made accessible to a defined community for reference or borrowing.
https://en.wikipedia.org/wiki/Library
© MrOwl Technologies, LLC. All rights reserved.
About Us Press Storage Plans Help Terms of Use	Privacy Policy Contact Us
You have logged out.


HomeResources Do I Need Payroll Services for my Small Business?
Do I Need Payroll Services for My Small Business?
This e-book covers it all — the top reasons to outsource payroll, signs that you need payroll services, how to pick the right payroll solution, payroll add-ons that will simplify your life and how to start using payroll services!


How to Play Roblox games on Xbox One and Mobiles? Roblox is played worldwide by millions North America.8MM Europe.9MM Asia Pacific.2MM Latin America.5MM Rest of World.8MM Roblox Promo Codes 2018 Not Expired Roblox Promo Code Hack Roblox..
Available in major cities and their outskirts, head over to the website or app and check out whether they deliver to your home. Ubereats isnt available in your city quite yet but were expanding soon. Ubereats find the latest deals, coupons, vouchers, promotional codes and offers for. . If you like great bargains, we've got you covered. Ubereats Promo Code Ubereats gets you the food you want from the restaurants you love, faster than anyone else. Uber is an international transportation network headquartered in San Francisco. Ubereats Promo Code For Existing Users / New Users 2018. Coupon: uber2oq, ubereats is currently available in, amsterdam.
Ubereats promo code to share with family and friends, and when they apply your code to their order you. Ubereats, promo, code, ubereats gets you the food you want from the restaurants you love, faster than anyone else. Ubereats promo code at checkout and save 20 off your order. Start saving from now!
Firstly, Welcome to our website. Get Deal save 5 promo code Enjoy 5 Off First Purchase More Click and grab this huge discount. Eats-zachw5340ue Show Code save 5 promo code 5 Off First Purchase More Use m Promo Code, select your dream products and save more. Ubereats Latest Promo Code Coupon Codes. 50 Ubereats coupons now. . 1257, coupons Available 18 verified coupons 866 used today, filter by, coupon Code (986). Eats-yonnab101ue Show Code save 5 promo code Enjoy 5 Off First Order More A big deal from m that you can't miss! The company enabled one to get taxi rides in minutes with no reservations or waiting in lines and recently launched its premium service known as ubereats. Ubereats Coupon 2018 Speed you need: By tapping into the Uber network, you can get anything from our roster of local restaurants, fast.


text:
#Monarchives
chavez storms to re-election victory
from reuters: Venezuelan President Hugo Chavez stormed to a re-election victory in Sunday's vote, handing him an ample mandate to broaden his promised socialist revolution and challenge Washington's influence in Latin America.
Dressed in his signature red shirt, Chavez told cheering supporters at his presidential palace late Sunday his landslide was a blow to U.S. President George W. Bush's administration, which portrays the leftist as an anti-democratic menace.
"Today we gave another lesson in dignity to the imperialists, it is another defeat for the empire of Mr. Danger," Chavez roared from a balcony above the crowds using one of the insults he has tossed at the U.S. president.
The former soldier's victory will further rile the White House, which worries about Chavez destabilizing Latin America neighbors and strengthening ties between the OPEC heavyweight Venezuela and U.S. foes Cuba and Iran.
The National Electoral Council said Chavez won 61 percent of the vote while rival Manuel Rosales, a governor of an oil-producing province who managed to unite the fractured opposition, won 38 percent after nearly 80 percent of the vote had been counted.
Chavez supporters fired off thunderous fireworks in the capital and drove through Caracas chanting "Hey ho, Chavez will not go" to celebrate his securing six more years in office.
TAGS: chavez, elections